QURE · uniQure N.V. · Stock research

Current Thesis

The regulatory story is repaired and the trade has already been paid out. On 2026-06-17 the FDA communicated, following a Type B meeting, that the three-year analysis from the AMT-130 Phase I/II study would be acceptable as the primary basis of a BLA for accelerated approval in Huntington's disease a direct reversal of the 2026-03-02 position that external-control data could not support a marketing application. UniQure guided to a Q3 2026 BLA and a Q3 2026 UK MAA. The stock spiked, management immediately sold $225M of equity into it at $45.50 (2026-06-24), and price has since bled back to $40.25 (2026-07-17) under the deal price, with the CEO selling on 2026-07-02. What is left is a funded, de-risked-on-paper filing story trading at $2.77B on $18.09M TTM revenue, waiting on a submission headline that has no date attached to it. The narrative leg an investor is buying now is not "will the FDA allow a filing" that is answered and priced but "does the BLA land in Q3 with a standard-of-care confirmatory design intact." That is a thinner, later, and more binary bet than the one available five weeks ago.

Bullish and bearish views on uniQure N.V.

The model's bull view on uniQure N.V. (QURE), in brief: Dated agency reversal, not sentiment. 2026-06-17: FDA accepts the three-year Phase I/II analysis as the primary basis for an accelerated-approval BLA; company guides submission to Q3 2026. The 2026-03-02 8-K had said the opposite. The confirmatory trial got materially cheaper.… The bear view: Price is under the deal. The $225M offering priced at $45.50 on 2026-06-24 (4,945,055 shares) with the stock around $48.60. At $40.25 every buyer of that book is offside. That converts $45.50 from a support shelf into overhead supply the first bid on any rally is the deal buyer… Both cases follow in full.

Bull Case

• Dated agency reversal, not sentiment. 2026-06-17: FDA accepts the three-year Phase I/II analysis as the primary basis for an accelerated-approval BLA; company guides submission to Q3 2026. The 2026-03-02 8-K had said the opposite.
• The confirmatory trial got materially cheaper. FDA is considering a concurrent standard-of-care control rather than the sham-surgery design demanded in March. Sham neurosurgery control is the single hardest enrollment problem in this indication; removing it shortens the path and cuts the burn attached to it.
• Efficacy is not the question. The June-2025 pivotal readout showed a statistically significant 75% slowing of disease progression on cUHDRS at 36 months at the high dose versus a propensity-matched external control. Huntington's has no approved disease-modifying therapy.
• Sell-side reset hard and has not walked it back. 2026-06-18: Barclays Overweight PT $65, Leerink Outperform PT $70, RBC Outperform PT $65, Goldman PT $14 → $46. 2026-06-25: Mizuho Outperform PT $68. 2026-06-29: H.C. Wainwright PT $50 → $80. Cantor Fitzgerald and Wells Fargo both moved to Overweight. Consensus average PT sits near $65 across 13 analysts (higher, ~$71, across broader 22-analyst panels) against $40.25 spot.
• Funded through the event. $586.6M cash and investments at 2026-03-31 plus ~$211.5M net from the June raise; runway guided into H2 2029; current ratio 10.40. No forced second raise before the filing decision.
• Second asset showing signal. AMT-260 (refractory mesial temporal lobe epilepsy) first-cohort data, 2026-06-22: early seizure reductions, no treatment-related serious adverse events.
• Sector regime corroborates. 2026-06-22: FDA reversed its rejection of REGENXBIO's Navsunli and permitted a refile a second data point on an agency flexing toward rare-disease gene therapy.
• Structure is still constructive underneath. Price holds above a rising 50-DMA at $34.03 and a 200-DMA at $29.45, golden cross intact, +179% over 52 weeks. Short interest at 16.72% of shares outstanding is real fuel if a filing headline lands.

Bear Case

• Price is under the deal. The $225M offering priced at $45.50 on 2026-06-24 (4,945,055 shares) with the stock around $48.60. At $40.25 every buyer of that book is offside. That converts $45.50 from a support shelf into overhead supply the first bid on any rally is the deal buyer getting out flat.
• Management raised equity into the spike and personally distributed into it in the same fortnight.
• A filing path is not an approval. The BLA must still be submitted, accepted, and reviewed, and FDA can re-attach conditions at any stage. The 15-week swing from the 2026-03-02 rejection of the external-control package to the 2026-06-17 acceptance shows the agency's stance on this file moves fast in both directions.
• The submission has no date. "Q3 2026" spans July through September. A name whose next real move requires an undated press release is a poor risk-of-ruin profile against a 16.72% short base that will press any slippage.
• Valuation carries no cushion. $2.77B market cap, $18.09M TTM revenue (-10.4%), -$208.87M net income, -$172.11M operating cash flow. Hemgenix contributes little. There is nothing to fall back on if the regulatory leg breaks.
• Dilution is structural, not one-off. 68.75M shares outstanding, +20.23% year over year. Approval-stage build-out and a confirmatory trial argue for more of it.
• Epilepsy read is thin. Six patients, up to six months follow-up, no control arm. It is a call option, not a second pillar.
• Adcomm risk is live in the sector. Capricor's Deramiocel got a July advisory-committee meeting scheduled on 2026-06-26 and the stock fell. An adcomm attached to AMT-130 would add a binary that is not currently in the price.

Setup & Price Structure

Last close $40.25 (2026-07-17, +2.26%), 52-week range $8.73–$71.50, +68.2% year to date from $23.93. The 50-DMA is $34.03 and the 200-DMA $29.45 both rising, both well below spot, so the trend template is technically intact even after the fade.

The structure is a V, not a base. Price ran from the March low through the 6/17 spike into the high $40s, then gave back roughly 17% into mid-July on no negative news. There is almost no price memory between $30 and $50 the tape moved through that band twice in four months without building a shelf, so pullbacks have nothing to lean on until the 50-DMA.

The battleground level is $45.50. A weekly close back above the offering price on expanding volume is the readable sign that the deal has been digested and the sellers are done; until that happens, rallies into the mid-$40s are meeting supply from a book that is underwater. On the downside, $34 is where the rising 50-DMA meets the pre-U-turn consolidation losing that on a weekly basis says the regulatory re-rate is being unwound rather than consolidated.

Beta of 0.90 is meaningless here. The realized distribution on this name is bimodal and headline-driven; the correct framing is a fully-funded filing story with a 16.72% short base and a wide, undated event window, which is why a starter-size approach and no adding into weakness are the only sane way to carry it.

Catalyst Calendar (next 30 days)

• ~2026-07-31 to 2026-08-04 (est.) Q2 2026 financial results and pipeline update. Q1 was reported 2026-05-05; calendars split between 7/31 and 8/4, so treat the whole window as live. The value is not the P&L but the management commentary on BLA timing and confirmatory-study design.
• Q3 2026, undated (any session from now) AMT-130 BLA submission to FDA. This is the actual catalyst and it can drop on any morning without pre-announcement.
• Rolling, no date confirmation (or contradiction) that the confirmatory study will run with a concurrent standard-of-care control rather than a sham-surgery arm. FDA wants alignment before the BLA goes in, so this headline should precede the filing.
• Q4 2026 (outside window, flagged) BLA acceptance / refuse-to-file decision, roughly 60 days after submission. That is the genuine binary; everything before it is positioning.

Elapsed catalysts

• Q3 2026, undated UK MAA submission to MHRA on the three-year data, following the 2026-04-30 pre-submission meeting. An independent, non-FDA route. _(passed 80d ago)_

What Would Change Our Mind

• Thesis-break condition: a weekly close below $34 — that surrenders the rising 50-DMA and the pre-U-turn consolidation, and would mark the June re-rate as being unwound rather than digested.
• Bullish confirmation instead: a weekly close above $45.50 on expanding volume, clearing the offering price and turning deal supply into support. That is the level at which the story re-earns size.
• BLA slipping out of Q3 2026 into Q4 or later, or Q2 commentary that hedges on submission timing.
• Any reversion of the confirmatory design to a sham-surgery control, which reinstates the March 2026 problem and the multi-year, high-burn path attached to it.
• A refuse-to-file, or an advisory committee being scheduled for AMT-130 the latter reads as agency hesitation and adds an unpriced binary.
• Continued insider distribution on top of the 2026-07-02 CEO sale, particularly non-10b5-1 sales.
• Competitive Huntington's data from PTC Therapeutics or Wave Life Sciences that compresses the first-mover premium the $65-ish consensus target is built on.

Correlation Notes

• RGNX (REGENXBIO) the 2026-06-22 Navsunli refile allowance is the purest read on whether the FDA's gene-therapy flexibility is durable or a one-file exception.
• CLPT (ClearPoint Neuro) supplies the neurosurgical delivery platform used for AMT-130; trades as a levered derivative of the AMT-130 commercial timeline. Divergence between the two is an early warning on filing conviction.
• CAPR (Capricor) the 2026-06-26 adcomm scheduling and subsequent selloff is the template for how this tape prices an unexpected advisory committee.
• SRPT, RCKT, TSHA, SLDB the AAV gene-therapy complex. A safety event anywhere in it (AAV liver toxicity, a clinical hold) hits the whole group regardless of program specifics.
• PTCT, WVE Huntington's competitors; positive competitor data is a direct negative here.
• XBI small-cap biotech beta. This name's regulatory-thaw premium survives a soft XBI tape but not a rate-driven one; it went to $8.73 in the last risk-off leg.
• Theme status: MATURING. Rare-disease gene-therapy regulatory thaw was accelerating from mid-June to end-June; the upgrades have landed, the equity has been raised, and price is now below where the deal cleared. That is the signature of a theme in its digestion phase, not its discovery phase.